Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass.

@article{Pireaux2019AnticoagulationWA,
  title={Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass.},
  author={Val{\'e}rie Pireaux and Jo{\"e}l Tassignon and St{\'e}phanie Demoulin and Sandrine Derochette and Nicolas Borenstein and Ang{\'e}lique Ente and Laurence Fiette and Jonathan Douxfils and Patrizio Lancellotti and Michel Guyaux and Edmond Godfroid},
  journal={Journal of the American College of Cardiology},
  year={2019},
  volume={74 17},
  pages={
          2178-2189
        }
}
  • Valérie Pireaux, Joël Tassignon, +8 authors Edmond Godfroid
  • Published in
    Journal of the American…
    2019
  • Medicine
  • BACKGROUND Exposure of blood to polyanionic artificial surfaces, for example, during cardiopulmonary bypass (CPB), induces a highly procoagulant condition requiring strong anticoagulation. Unfractionated heparin (UFH) is currently used during CPB but can lead to serious bleeding complications or development of a hypercoagulable state culminating in life-threatening thrombosis, highlighting the need for safer antithrombotics. Ixodes ricinus contact phase inhibitor (Ir-CPI) is a protein expressed… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv